A0301 - NMR-based metabolomics discriminate between prostate biopsy-positive and biopsy-negative patients suspicious for prostate cancer

Autor: Ladurner, M., Ameismeier, T., Klocker, H., Steiner, E., Hauffe, H., Wittmann, J., Drettwan, D., Eder, I.

Publikováno v: In European Urology March 2024 85 Supplement 1:S1097-S1097

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An NMR-based metabolic signature to identify clinically significant prostate cancer in patients undergoing biopsy.

Autor: Ladurner M; Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria., Ameismeier T; lifespin GmbH, Am Bio Park 13, 93053 Regensburg, Germany., Klocker H; Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria., Steiner E; Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria., Hauffe H; Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria., Aigner GP; Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria., Neuwirt H; Department of Internal Medicine IV Nephrology and Hypertension, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria., Böld T; lifespin GmbH, Am Bio Park 13, 93053 Regensburg, Germany., Strathmeyer S; lifespin GmbH, Am Bio Park 13, 93053 Regensburg, Germany., Heidegger I; Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria., Drettwan D; lifespin GmbH, Am Bio Park 13, 93053 Regensburg, Germany., Eder IE; Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.

Publikováno v: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Oct 09. Date of Electronic Publication: 2024 Oct 09.